Refining drug administration in a murine model of acute infection with Trypanosoma cruzi by Gulin, Julián Ernesto Nicolás et al.
METHODOLOGY Open Access
Refining drug administration in a murine
model of acute infection with Trypanosoma
cruzi
Julián Ernesto Nicolás Gulin1,2* , Margarita Bisio1,2 and Facundo García-Bournissen1,2
Abstract
Background: In animal research, “refinement” refers to modifications of husbandry or experimental procedures to
enhance animal well-being and minimize or eliminate pain and distress. Evaluation of drug efficacy in mice models,
such as those used to study Trypanosoma cruzi infection, require prolonged drug administration by the oral route
(e.g. for 20 consecutive days). However, the orogastric gavage method can lead to significant discomfort, upper
digestive or respiratory tract lesions, aspiration pneumonia and even accidental death. The aim of this work was to
evaluate the effect of two administration methods (conventional oral gavage vs. a refined method using a
disposable tip and automatic pipette) on the efficacy of benznidazole in a murine model of T. cruzi infection.
Results: Both administration methods led to a rapid and persistent reduction in parasitaemia. Absence of T. cruzi
DNA (evaluated by real-time PCR) in blood, cardiac and skeletal muscle confirmed that treatment efficacy was not
influenced by the administration method used.
Conclusions: The proposed refined method for long-term oral drug administration may be a suitable strategy for
assessing drug efficacy in mice models of Chagas disease and can be applied to similar murine infection models to
reduce animal discomfort.
Keywords: Chagas disease animal models, Chronic treatment - Oral administration, Preclinical drug research,
Refinement
Background
Drug administration by the oral route is a common
method to achieve systemic exposure. Substances can be
delivered to the gastrointestinal tract by including them
in water or food, by oropharyngeal administration of
capsules, pills or fluids, or through gavage [1] requiring
physical restraint by trained staff to minimize animal
harm and stress.
When a research protocol requires chronic oral drug
administration, inclusion in food or water may be pos-
sible, but may increase variability and uncertainty in the
ingested dose, reducing dosing accuracy. In addition,
many compounds are not water-soluble, and environ-
mental conditions such as temperature and humidity
can affect stability [2].
Oral gavage delivers a known drug amount in a single
administration step. Though effective, it requires sub-
stantial technical skills, is very labor-intensive and is not
suitable for long-term and/or frequent treatments. Dis-
advantages of gavage dosing include risks of esophageal
or stomach damage and inadvertent administration into
the airway using both house-made and commercial de-
vices systems [3].
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In animal research, “refinement” refers to “modifica-
tions of husbandry or experimental procedures to en-
hance animal well-being and minimize or eliminate
pain and distress” [4]. While many efforts have been
done to refine post-surgical analgesia administration
[5, 6] to minimize stress interference in behavior
studies [7] or in neuroleptic therapy models [8] there
is still a lack of information on the bias that less in-
vasive oral administration methods may introduce in
parasitology models.
Treatment options for Chagas disease rely on benzni-
dazole (BZ) and nifurtimox (NFX), developed over four
decades ago and still the only available chemotherapy,
with potential severe adverse effects. Thus, there is an
urgent need for new and better chemotherapy for this
endemic parasitic disease [9].
In this context, a consensus for pre-clinical drug
discovery for Chagas disease has emerged, which
proposes a 20 consecutive day treatment protocol
using the oral route to evaluate the efficacy of new
anti-Trypanosoma cruzi compounds in the murine
model of acute infection [10].
To alleviate potential drawbacks of the gavage method,
we developed a refined method of oral administration
using a disposable tip and automatic pipette. The aim of
this work is to compare both oral administration
methods (i.e. oral gavage vs. the refined method using a
disposable tip with an automatic pipette) on the efficacy
of BZ in a murine model of T. cruzi infection during a
twenty-consecutive day protocol.
Results
Animal welfare
Benznidazole treatment was well tolerated by mice
throughout the study whatever the administration
method. Weight and body temperature were registered
regularly and there were no statistical differences be-
tween both administration methods (data not shown).
Mice receiving treatment through traditional oral gavage
displayed aversion to the procedure and the discomfort
lasted for the 10–15 min after dosage (noted as immobil-
ity, gagging and respiratory distress). Conversely, the re-
fined method was well accepted and all mice received
the full volume of the drug. Mice treated with the re-
fined method seemed normal and resumed their usual
behavior immediately after drug administration. There
was no damage observed on the hard palate during or
immediately after drug administration and there no sub-
stance loss during the treatment. All mice survived the
treatment period in both administration methods.
Treatment and assessment of cure
Parasitaemia was evaluated daily starting on the 7th day
post-infection (dpi) by direct microscopy. All infected
animals displayed patent parasitaemia at 12 dpi, and BZ
treatment started immediately (Fig. 1). Since Shapiro-
Wilk tests analysis showed that parasitaemia values did
not approximate to normality (p = 0.43 for TIP p = 0.53
for GAV), nonparametric tests were used for analysis.
Acute infection was established similarly in both
groups. Although at treatment onset TIP group had
Fig. 1 Parasitaemia curve in infected mice treated with benznidazole using gavage (GAV) or tip method (TIP)
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significantly higher mean parasitaemia values than GAV
(4.84 × 105 vs. 2.28 × 105; p = 0.03; Mann-Whitney) para-
sitaemia course was similar between experimental
groups and as expected with the acute phase of infection
by the T. cruzi VD strain (Fig. 1).
A median of 4 BZ doses (range 1 to 5 doses) were
needed to reach parasitaemia clearance in the TIP ad-
ministration group, while and in the GAV group, a me-
dian of 5 BZ doses were required (range 1 to 5 doses).
The number of doses to achieve parasitaemia clearance
were not statistically different (p = 0.59; Mann Whitney
test). At the end of treatment, (i.e., 31 dpi), all animals
had negative parasitaemia by direct blood observation
and no mortality was observed in any group.
Similarly, no differences were detected in median pa-
tent parasitaemia period between both administration
methods: 4 days for TIP group (range 1 to 9 days) and 8
days for GAV group (range 1 to 8 days) (p = 0.88;
Mantel-Cox log rank sum) (Fig. 2).
Immunosuppression cycles started at 43 dpi and were
repeated at 50, 57 and 64 dpi. As no mice developed re-
bound parasitaemia by direct blood examination, para-
sitological cure was explored by qPCR in blood, heart,
and skeletal muscle (Table 1). All heart samples but one
(from GAV group) were negative while skeletal muscle
samples were negative or below the limit of quantitation
by qPCR therefore the animals were considered cured.
Discussion
This work was conducted to validate the efficacy and
safety of a new, simple and low-cost method for daily
oral drug administration using a murine model of T.
cruzi acute infection. This method is potentially transfer-
able to other rodent preclinical studies.
This refined strategy involves using a disposable tip
and automatic pipette, which allows selecting final vol-
ume to the minimum required volume to dissolve the
compound (e.g.: 20 or 50 μL), avoiding animal exposure
to unnecessarily large volumes. Although this refined
method is already in use in our protocols, we thought
that it would be important to validate it in order to use
it as a routine procedure for long-term oral drug admin-
istration in drug research and development.
To the best of our knowledge, up to now there were
no studies evaluating compound efficacy in animal
models of infectious or parasitological diseases while
using a more refined oral administration method. Previ-
ous work reported morbi-mortality caused by repeated
oral gavage drug administration in a murine model of T.
cruzi infection, a situation that can potentially distort
valuable results when studying new chemotherapies for
Chagas disease and other diseases [11].
The refined oral administration method offers many
advantages over conventional gavage administration,
such as less animal handling time, less intensive operator
training and, most important, reduced risk of upper re-
spiratory and digestive tract damage or aspiration pneu-
monia in those protocols that require chronic oral
compound administration. In addition, this method al-
lows for accurate individual dose and volume tailoring.
A similar refined technique was described for 15 and
40 days-old rats previously trained for water deprivation
with good acceptance [7]. Unlike this report, none of the
animals in our study refused to drink BZ compound and
there was no needed to train the animals nor submit to
water deprivation period prior to dosing.
A potential disadvantage of this method is that treat-
ment acceptance by the animals would be dependent on
Fig. 2 Cumulative median time to parasitaemia clearance in mice infected with Trypanosoma cruzi
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drug palatability, which may add variability to the effi-
cacy depending on the taste of the drug and physico-
chemical characteristics of the administered solution
with transient discomfort and a higher risk of substance
loss. Although this situation was no observed in our
work, palatability is a factor to consider prior to estab-
lishing a more refined technique procedure [12].
This acute model of T. cruzi infection was previ-
ously standardized and the employed VD strain shows
high parasitaemia levels and high mortality rates in
non-treated (NT) infected BALB/c mice [13]. Then,
for this work, there was no NT group added since
the aim was to present an alternative oral administra-
tion method with a reference drug. BZ was chosen
for our study based on the proven efficacy and
current use in experimental models and clinical cases
of Chagas disease [10, 14].
BZ effectiveness (i.e. parasitological cure) was estab-
lished both by the absence of rebound parasitaemia after
immunosuppression and quantifiable parasite DNA de-
tection in blood and target tissues assessed by qPCR.
The absence of parasitaemia rebound was confirmed by
qPCR and all blood samples were negative irrespective
of the administration method.
Although T. cruzi DNA was detected in some samples
from cardiac and skeletal muscle from both groups, the
obtained signal was below the quantitation limit. It is
important to note that VD strain shows a high tropism
for skeletal muscle and therefore many T. cruzi DNA
may be present at the site of infection [13]. Persistence
of parasite DNA detectable but not quantifiable was
consistent with parasitological cure in our model, as
these results can be explained by the persistence of T.
cruzi DNA in local phagocytes (as documented in previ-
ous studies [15] that may represent intra and/or extra-
cellular granular antigens, abundant in heart and skeletal
muscle during the acute phase of the infection [16].
CYP is a commonly used agent to establish immuno-
depletion in mice [10]. Two CYP injections at 150 mg/kg
by intraperitoneal route are enough to produce severe
leukopaenia [17]. Thereby, the CYP protocol used in our
work can be considered enough to lead to parasitaemia
rebound if there were any persisting parasites in sanctu-
ary sites, such as heart and skeletal muscle due to BZ
failure.
Previous studies in other experimental models have
yielded similar observations. In a murine Echinococcus
multilocularis experimental model, albendazole serum
concentrations were similar when administered either by
gavage or by voluntary ingestion in honey mixture, and a
comparable antiparasitic activity achieved [2].
Although no pharmacokinetic analyses have been done
yet, our results suggest than BZ efficacy is not affected
by either administration method, and given the rapid ab-
sorption of oral BZ into circulation it is unlikely that sig-
nificant pharmacokinetics differences would exist among
both methods [18].
Due to the lack of similar studies, there was no previ-
ous data available on which to base an a priori power
analysis. Moreover, our experimental outcome was a cat-
egorical variable (cured/no cured dichotomy), hampering
sample size estimation beforehand. Accordingly, we as-
sumed that the refined administration method should be
as effective as the standard. Considering a complete
treatment response in mice treated with BZ by gavage
method (gold standard), it would be unacceptable to ob-
tain biased results due to the administration method
apart from the drug activity.
Conclusions
As no significant differences were detected in drug effi-
cacy between both administration methods, this refined
technique consisting on administration with a tip and
automatic pipette seems like a reliable method for BZ
daily oral administration in an acute experimental mur-
ine model of T. cruzi infection while not affecting the
experimental outcome and it could even be applied to
similar murine models of related infectious or parasitic
diseases.
Material and methods
Animals
Twenty-one days-old BALB/cJ male mice obtained from
Animal Facilities (Faculty of Veterinary Sciences,
Table 1 Trypanosoma cruzi detection after immunosuppression cycle in a murine model of acute infection
Administration
method
Number
of mice
with
parasite
rebound
FBE (%)
Number of mice with quantifiable T. cruzi DNA (%) Mice with
parasitological
cure (%)
Blood Skeletal muscle Heart
GAV 0 / 5 (0%) 0 / 5 (0%) 0 / 5 (0%)
(4a)
1 / 5 (20%)
(1a)
5 / 5 (100%)
TIP 0 / 5 (0%) 0 / 5 (0%) 0 / 5 (0%)
(3a)
0 / 5 (0%) 5 / 5 (100%)
FBE fresh blood examination, GAV oral administration method by gavage, TIP oral administration method by pipette and tip
a Number of samples with T. cruzi DNA detectable but below the quantization limit (Ct > 30)
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University of Buenos Aires) were housed under conven-
tional closed barriers at Dr. Ricardo Gutiérrez Buenos
Aires Children’s Hospital animal facilities. Animals were
acclimatized to new housing conditions and habituated
to routine handling by trained personnel for 7 days prior
to the experiment.
Mice were individually identified and housed in prop-
erly labelled, 600 cm2 polycarbonate cages at 5 mice per
cage. Cages were filled with irradiated chip-bedding and
changed once a week. Mice had ad libitum access to
food (Rata-Ratón Cooperación®, Argentina) and water
filtered by reverse osmosis. Macroenvironmental condi-
tions included 12:12-h light: dark cycle (starting at 6
a.m.), a controlled temperature in a range of 20 to 22 °C,
and humidity from 45 to 55%.
The study protocol was approved by the Institutional
Animal Care and Use Committee from the Faculty of
Veterinary Sciences – University of Buenos Aires (#
Protocol: 2014/4).
Experimental infection
Mice (28–35 days old; 20.12 ± 2.35 g) were infected with
1000 bloodstream trypomastigotes of T. cruzi VD strain,
previously characterized [13] and maintained by serial
passages in outbred CF-1 male mice. The inoculum was
suspended in sterile RPMI-1640 medium and adminis-
tered in a final volume of 0.2 mL per animal by intraper-
itoneal (ip) route. Treatment started at 12 days post
infection (dpi), when all infected animals exhibited
bloodstream trypomastigotes and it was randomly
assigned as follows: GAV: BZ administered by gavage
(n = 5); or TIP: BZ administered by a disposable tip and
automatic pipette (n = 5).
Drug and treatment administration
BZ commercial tablets (Radanil®, Roche) were crushed
and suspended in a 0.25% solution of sodium carboxy-
methyl cellulose (Sigma-Aldrich Co.). Treatment was
administered orally at a dose of 100mg/kg/day for 20 con-
secutive days, between 10 and 11 a.m. All animals were
weighed at least once a week, and drug doses adjusted for
weights. Dose, length of treatment and route of adminis-
tration were chosen based on published data [10].
For gavage dosing, a disposable and flexible gavage
with an 8–10 cm long 35 K nasogastric tube was pre-
pared. This device was then coupled to a 1 mL syringe.
The oral gavage technique was carried out as previously
described [1] (Fig. 3a).
Pipette tip administration was performed with dispos-
able tips (Kima®, Italy, #18170) and a 200 μL volume
automatic pipette. This refined administration technique
consisted in filling the pipette with the drug solution at
the corresponding volume, along with physical restrain-
ing of the mouse with the least skilful hand and the pip-
ette in the other hand. Then, the tip was slightly
approached to the animal’s mouth and the volume was
discharged slowly into the oral cavity, while gently press-
ing the hard palate with the tip to stimulate the swallow-
ing reflex (Fig. 3b). The procedure was usually fast, and
restraint was limited to less than 30 s since the volume
to be dispensed was generally low (50–100 μL).
Assessment of treatment response
Parasitaemia was evaluated since 7 dpi every day until it
became negative for at least three consecutive days,
using a modified Pizzi-Brener method [19–21]. A total
of 5 μL of blood was taken by amputation of the tail tip.
Fig. 3 Mice receiving oral dosing of benznidazole
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In the successive sampling, the clot was removed and
the blood was extracted by milking the tail gently [22].
Then, the sample was compressed between a glass
slide and an 18 × 18 mm coverslip and examined
microscopically at × 400 magnification. The number of
parasites per mL of blood was determined by counting
trypomastigotes in 50 fields and then multiplying that
number by a conversion factor (104) to express the result
in terms of trypomastigotes/mL. This technique allows
detecting a minimum of 10,000 trypomastigotes/mL.
Patent period (defined as the time elapsed between para-
sitaemia onset and parasitaemia clearance) and the num-
ber of doses to obtain parasite clearance were also
recorded.
After treatment was completed, animals with un-
detectable parasitaemia were left without treatment for
10 days, with regular blood testing for re-emergence of
bloodstream parasites, and then subjected to a cyclo-
phosphamide (CYP)-based immunosuppression protocol
to rule out parasite recurrence from sanctuary sites in
tissues. Immunosuppression protocol consisted of 4
cyclophosphamide administrations (CYP) (Filaxis La-
boratory, Buenos Aires, Argentina), at 200 mg/kg by ip
route, separated by 7 days [23].
Parasitaemia was evaluated weekly during immuno-
suppression; finally, animals that remained negative were
euthanized with sodium thiopental (Hipnopento®, Dr.
Gray Products, Argentina) at 300 mg/kg by ip route. At
the moment of euthanasia blood, skeletal and heart
muscle were collected for T. cruzi-DNA testing by real-
time PCR (qPCR).
Preparation of peripheral blood and tissues for qPCR
One hundred microlitres of blood were obtained by sub-
mandibular vein puncture [24], collected in a sterile tube
and mixed immediately with 200 μL of guanidine 6M
EDTA 0.2M buffer. Rear legs skeletal and heart muscle
samples (25–50 mg) were obtained with sterile scissors
and were rinsed with sterile distilled water before collec-
tion into separated DNase-free tubes. Samples were
stored at − 20 °C until processing.
DNA preparation and q-PCR
Total genomic DNA was extracted from blood and tis-
sues using the High Pure PCR Template Preparation Kit
(Roche®). T. cruzi DNA amplification was performed on
a StepOne PCR system (Applied Biosystems®) as de-
scribed elsewhere [25]. Amplification product detection
was performed using TaqMan® probe cruzi 3 labelled
with 5’FAM (6 – carboxyfluorescein) and 3’MGB (minor
groove binder).
Each 48-well reaction plate contained two positive and
two negative controls. Negative controls consisted of a
reaction with T. cruzi-specific primers without DNA and
with DNA extracted from blood or tissues from non-
infected mice. PCR standard curves were generated by
inoculating specimens with 8 × 105 trypomastigotes of T.
cruzi VD strain, followed by DNA extraction and serial
dilutions. The standard curve allowed DNA quantifica-
tion in the range of 1.6 × 100 to 8 × 105 parasite equiva-
lents/mL. Amplification efficiencies were determined by
StepOne Software v2.1 (Applied Biosystems®) by calcu-
lating efficiency (E) = 10(− 1/slope). Parasite loads in indi-
vidual specimens were calculated based on the standard
curve included in each batch run.
Experimental design and statistical analysis
No previous information was available to estimates the
sample size and power analysis for this pilot study. Thus,
the sample size was based on published suggestions to as-
sess the efficacy of new compounds in mice models of T.
cruzi infection [26]. Male mice were chosen since they are
known to be more susceptible to T. cruzi infection than
females, which would maximize the chances to observe a
difference in response between interventions [27].
Each experimental group was composed of 4- and 5-
weeks old mice at the moment of infection, and each
cage was occupied by animals from different experimen-
tal groups, unequivocally identified.
Nonparametric tests were used when graphical inspec-
tion of data Shapiro-Wilk test indicated that data did
not approximate to normal distribution and could not
be transformed to meet assumptions for parametric
analyses.
Non-parametric Mann-Whitney test was performed to
assess differences in maximum parasitaemia values, and
number of doses needed to achieve parasitaemia
clearance between both administration methods, while
differences in patent parasitaemia was analyzed with
Mantel-Cox rank test. The statistical significance level
was determined a priori at a P-value <0.05. Values are
expressed as median and range. All analysis and graphics
were performed with GraphPad Prism (GraphPad Prism,
Version 5.03 for Windows, Graph- Pad Software, San
Diego, CA, USA; www.graphpad.com).
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